Company intelligence / Profile preview

Zhengzhou Fortune Bioscience

Zhengzhou, Henan, China

Ownership: Private
Development stage: Other

Overview

Zhengzhou Fortune Bioscience is a China-based in vitro diagnostics manufacturer specializing in point-of-care lateral flow tests (e.g., pregnancy, fecal occult blood, drugs of abuse, and infectious diseases) with ISO 13485-certified facilities and tens of millions of monthly test capacity; it also serves as OEM manufacturer for Sorrento’s COVISTIX rapid COVID-19 antigen test, which is approved or authorized in multiple countries and regions.[1][3][5][6]

Therapeutic areas: PsychiatryInfectious DiseasesWomen's HealthGastroenterology
Modalities: DeviceDiagnostic test
Industry: Molecular Diagnostics

Partnerships

Sorrento Therapeutics (OEM manufacturing and majority ownership; exclusive OEM manufacturer for COVISTIX COVID-19 rapid antigen test)[5]

Beyond the preview

Go deeper on Zhengzhou Fortune Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengzhou Fortune Bioscience.

Explore the full profile